Abstract
AbstractBackgroundThe management of pain in patients with advanced liver disease is a clinical challenge. Initial pharmacokinetic safety data advised against the use of oxycodone–naloxone in this population, but in clinical practice it is commonly used. Our case aims to illustrate a potential mechanism by which administration of oxycodone–naloxone can cause systemic opioid antagonism and harm to patients.Clinical detailsA 45‐year‐old man received two separate doses of oxycodone–naloxone in the immediate postoperative setting, resulting in symptoms and signs consistent with acute opioid withdrawal. A review of his imaging revealed significant portosystemic shunts.OutcomesPortosystemic shunts in patients with advanced liver disease may lead to a decrease in the Phase II hepatic metabolism of naloxone and increased systemic levels. In the case of someone with pre‐existing opioid dependence, this may precipitate acute opioid withdrawal.ConclusionThe use of oxycodone–naloxone preparations should be avoided in patients with liver disease and portosystemic shunts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
